Examkin

Soru

Zorluk: OrtaHematology and Oncology

A 58-year-old man with a known history of advanced squamous cell carcinoma of the lung is brought to the emergency department by his family due to progressive confusion, severe lethargy, and frequent urination over the past three days. His blood pressure is 85/55 mmHg, heart rate is 118/min, and respiratory rate is 18/min. Physical examination demonstrates dry mucous membranes and markedly decreased skin turgor. Laboratory studies show a serum calcium level of 15.2 mg/dL and a serum albumin level of 3.5 g/dL. An electrocardiogram reveals a shortened QT interval.

Arrange the following management steps in the optimal sequential order, from the most immediate initial intervention to the long-term definitive therapy.

  1. 1Initiate rapid intravenous volume expansion with isotonic normal saline.
  2. 2Administer subcutaneous calcitonin.
  3. 3Administer an intravenous bisphosphonate (e.g., zoledronic acid).
  4. 4Consult medical oncology to initiate targeted antineoplastic therapy.

Cevap

The correct sequence is: 1) Initiate rapid intravenous volume expansion with isotonic normal saline, 2) Administer subcutaneous calcitonin, 3) Administer an intravenous bisphosphonate, and 4) Consult medical oncology to initiate targeted antineoplastic therapy.
The management of severe hypercalcemia (calcium > 14 mg/dL) follows a strict temporal algorithm dictated by the pharmacokinetics and safety profiles of the interventions. The absolute first step is aggressive volume expansion with isotonic saline, as patients are profoundly dehydrated from hypercalcemia-induced nephrogenic diabetes insipidus. Hydration immediately improves hemodynamics and enhances renal calcium clearance. Second, calcitonin is administered for its rapid onset of action (4 to 6 hours), lowering calcium quickly by inhibiting osteoclast activity. Third, an intravenous bisphosphonate (such as zoledronic acid) is given; it provides the most potent and sustained reduction in serum calcium but has a delayed onset of 48 to 72 hours. Finally, once the patient is acutely stabilized, definitive treatment involves targeted antineoplastic therapy to eliminate the tumor producing the parathyroid hormone-related peptide (PTHrP).

Adım Adım Çözüm

1
Identify the primary clinical problem and assess its severity.
The patient has severe hypercalcemia of malignancy (calcium > 14 mg/dL) complicated by profound volume depletion.
Symptomatic hypercalcemia presents with central nervous system depression and induces nephrogenic diabetes insipidus, causing life-threatening dehydration and hypotension.
2
Determine the most critical first step in medical stabilization.
Aggressive intravenous hydration with isotonic normal saline must be started immediately.
Restoring intravascular volume is the fastest way to stabilize hemodynamics, restore renal perfusion, and increase the renal excretion of calcium.
3
Select the appropriate pharmacologic agents to lower calcium based on their onset of action.
Administer calcitonin followed by an intravenous bisphosphonate.
Calcitonin lowers calcium rapidly (within hours) but its efficacy wanes after 48 hours due to tachyphylaxis. Bisphosphonates take 48 to 72 hours to reach maximum effect and provide sustained control.
4
Determine the long-term definitive management strategy.
Initiate targeted antineoplastic therapy.
Treating the underlying malignancy (the source of the PTHrP) is strictly necessary to prevent recurrent episodes of hypercalcemia.

Anahtar Kavram

Algorithm for the acute management of severe hypercalcemia of malignancy
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru